Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds

Two High-Risk Prostate Cancer Treatments Have Similar Benefits, Add-On Study Finds
Two treatment approaches — Zytiga (abiraterone acetate) plus prednisolone (AAP) or Taxotere (docetaxel) — provided patients with high-risk prostate cancer similar benefits when added to standard hormone deprivation therapy, according to data recently presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain. While progression-free survival and other short-term measures slightly favored AAP, there was no difference in overall survival among patients treated with the two approaches. This leaves it up to oncologists to decide which treatment to opt for, researchers said, a decision that will likely be guided by availability and patient preferences. The study, “
Subscribe or to access all post and page content.